Summary

This BMJ investigation asks whether the US claim of medical agreement on treating gender distress in young people is backed by evidence. Block looks at the three most-quoted US guidance documents (from WPATH, the American Academy of Pediatrics and the Endocrine Society) and interviews experts on how they were made. Research reviews behind these guidelines rated the evidence for teenagers as low or very low quality, yet strong recommendations were made, and the pediatrics statement was not based on a formal review of the research. Meanwhile Sweden, Finland and NHS England were restricting medical treatment. It documents real weaknesses in the US guidelines and showed a major journal took the debate seriously. But it is journalism: the reporter chose the sources and examples, some figures (such as 20–30% stopping hormones) come from limited studies, and some readers called it biased.

Key findings

• Amerikanske lægeforeninger (WPATH, American Academy of Pediatrics og Endocrine Society) støtter pubertetsblokkere, krydskønshormoner og i nogle tilfælde kirurgi for mindreårige, mens Sverige og Finland gik over til at sætte psykologisk behandling først og begrænse kirurgi til voksne.
• Endocrine Society brugte et formelt system til at vurdere evidens og vurderede evidensen for alle sine anbefalinger til teenagere som ‘lav’ eller ‘meget lav’, men kom alligevel nogle gange med stærke anbefalinger. Gordon Guyatt, medstifter af det vurderingssystem, sagde, at det bør være sjældent og forklares tydeligt.
• WPATH's retningslinjer fra 2022 har intet system til at vurdere evidens. Retningslinjeeksperten Mark Helfand fandt udsagn ‘i modstrid med’ retningslinjens egne forskningsgennemgange, som vurderede evidens for hormoners effekt på livskvalitet, depression og angst som lav kvalitet.
• Hovedforfatteren til American Academy of Pediatrics' politikerklæring fra 2018 sagde, at processen ikke helt kunne regnes som en formel gennemgang af forskningen. Cochrane, en førende gruppe for evidensgennemgange, afslog at udgive en foreslået gennemgang af pubertetsblokkere efter ekspertkontrol.
• En sammenfatning fra McMaster University af 61 forskningsgennemgange, betalt af Floridas Medicaid (offentlig sygeforsikring), fandt ‘stor usikkerhed’ om blokkere, hormoner og kirurgi hos unge.
• To nyere studier (en revision af en britisk almen lægepraksis og amerikanske militære apoteksjournaler) tydede på, at 20-30 % af patienterne kan stoppe hormoner inden for få år, men de målte ophør, ikke fortrydelse eller detransition.
• Behandlere beskrev hurtigere medicinsk behandling og mindre psykisk vurdering. I et studie på Seattle Children's klinik var to tredjedele af teenagerne på hormoner inden for 12 måneder efter deres første besøg.

Conclusion

This investigative report from The BMJ concludes that despite claims of consensus, gender-affirming medical treatments for minors with gender dysphoria lack strong evidence-based support. Key findings include: (1) US medical organizations (WPATH, AAP, Endocrine Society) endorse gender-affirming care including puberty blockers, hormones, and surgeries, while several European countries (Sweden, Finland, France, UK) have moved to restrict medical interventions for minors, prioritizing psychological care; (2) systematic reviews commissioned by guideline bodies found evidence quality to be "low" or "very low," with experts criticizing the misapplication of "evidence-based" labeling to recommendations not meeting rigorous standards; (3) the surge in treatment of minors—particularly birth-registered females with no prior history of gender dysphoria—has outpaced research, with long-term outcomes unknown and detransition rates potentially as high as 20-30%; (4) clinical practice has shifted toward rapid medicalization, with concerns about inadequate assessment and perfunctory informed consent processes; and (5) prominent evidence-based medicine experts conclude that when rigorous systematic reviews find "we don't know," claims of certainty are not evidence-based, and consensus-based guidelines should not be called evidence-based.